BEAM THERAPEUTICS INC.

Beam Therapeutics Inc. a biotechnology company engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201 an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301 a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302 a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc. focus on in vivo base editing programs for targets rare genetic diseases of the liver muscle and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs including the eye liver and brain; Verve Therapeutics Inc. for cardiovascular disease treatments; Sana Biotechnology Inc. to research develop and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge Massachusetts.